ArticleMolecular therapy. Nucleic acids2020
CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral Replication.
Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 77 citations in OpenAlex.
- Development of attenuated and inactivated Dengue strains using advanced gene editing tools.Molecular biology reports · 2026Review
- Beyond DNA editing: how Cas13 redefined programmable RNA manipulation and what still limits its therapeutic promise.Nucleic acids research · 2026Review
- Engineered CRISPR-Cas13a system with enhanced target RNA cleavage activity and reduced collateral activity for therapeutic applications.Molecular therapy. Nucleic acids · 2026Article
- Anti-RNA virus crRNA targets efficient screening platform based on bioinformatics and CRISPR detection.Molecular therapy. Nucleic acids · 2025Article
- CRISPR/Cas13-Based Anti-RNA Viral Approaches.Genes · 2025Review
- CRISPR antiviral inhibits neurotrophic JC polyomavirus in 2D and 3D culture models through dual-gRNA excision by SaCas9.Molecular therapy. Nucleic acids · 2025Article
- Rapid visual detection and differentiation of canine and feline parvovirus via a one-tube RPA-CRISPR/Cas13a assay.Frontiers in microbiology · 2025Article
- Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology.Frontiers in genome editing · 2025Review
- Detection assay of polymyxin resistance codingFrontiers in cellular and infection microbiology · 2025Article
- Protection of animals against devastating RNA viruses using CRISPR-Cas13s.Molecular therapy. Nucleic acids · 2024Article
- mRNA-encoded Cas13 can be used to treat dengue infections in mice.Nature microbiology · 2024Article
- mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA.PLoS pathogens · 2024Article
- Suppression of Borna Disease Virus Replication during Its Persistent Infection Using the CRISPR/Cas13b System.International journal of molecular sciences · 2024Article
- Modulation of Equid Herpesvirus-1 Replication DynamicsViruses · 2024Article
- Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications.Virus research · 2024Review
- Effective inhibition of dengue virus replication using 3'UTR-targeted Vivo-Morpholinos.Frontiers in immunology · 2024Article
- Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.Biochemistry · 2023Review
- CRISPR-Cas system to discover host-virus interactions in Flaviviridae.Virology journal · 2023Review
- Rapid detection of Nipah virus using the one-pot RPA-CRISPR/Cas13a assay.Virus research · 2023Article
- AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice.EBioMedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CRISPR-Cas9 system has been applied to DNA editing with precision in eukaryotic and prokaryotic systems, but it is unable to edit RNA directly. A recently developed CRISPR-Cas13a system has been shown to be capable of effectively knocking down RNA expression in mammalian and plant cells. In this study, we employ the CRISPR-Cas13a system to achieve reprogrammable inactivation of dengue virus in mammalian cells. Quantitative reverse transcription PCR (qRT-PCR), fluorescence-activated cell sorting (FACS), and plaque assays showed that CRISPR RNA (crRNA) targeting the NS3 region led to the greatest viral inhibition among 10 crRNAs targeting different regions along the dengue viral genomic RNA. Deletions and insertions had also been found adjacent to the NS3 region after NS3-crRNA/Cas13a complex transfection. Our results demonstrate that the CRISPR-Cas13a system is a novel and effective technology to inhibit dengue viral replication, suggesting that such a programmable method may be further developed into a novel therapeutic strategy for dengue and other RNA viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.